These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15576036)

  • 1. Structural basis for the activity of drugs that inhibit phosphodiesterases.
    Card GL; England BP; Suzuki Y; Fong D; Powell B; Lee B; Luu C; Tabrizizad M; Gillette S; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
    Structure; 2004 Dec; 12(12):2233-47. PubMed ID: 15576036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
    Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
    Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
    Lau JK; Li XB; Cheng YK
    J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
    Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
    Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
    Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
    Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
    Wang Y; Ke H
    Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
    Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
    Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
    Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of cyclic nucleotide hydrolysis in the phosphodiesterase catalytic site.
    Salter EA; Wierzbicki A
    J Phys Chem B; 2007 May; 111(17):4547-52. PubMed ID: 17425352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
    Gupta R; Kumar G; Kumar RS
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
    Matthiesen K; Nielsen J
    Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
    Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
    Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
    Zhu J; Yang Q; Dai D; Huang Q
    J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
    Weeks JL; Corbin JD; Francis SH
    J Pharmacol Exp Ther; 2009 Oct; 331(1):133-41. PubMed ID: 19641165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
    Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
    J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Discovery of PDEs Inhibitors.
    Li L; Chen W; Chen T; Ren J; Xu Y
    Curr Top Med Chem; 2016; 16(9):917-33. PubMed ID: 26303429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional comparisons of nucleotide pyrophosphatase/phosphodiesterase and alkaline phosphatase: implications for mechanism and evolution.
    Zalatan JG; Fenn TD; Brunger AT; Herschlag D
    Biochemistry; 2006 Aug; 45(32):9788-803. PubMed ID: 16893180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
    Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.